Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 12, 2024Medical Cannabis and CannabinoidsOpen Access

Treatment of neuropsychiatric symptoms in Alzheimer’s disease with a cannabis-based magistral formulation: An open-label prospective cohort study

View Full Paper
Ask AI
Bookmark
Share

Authors

CNCristian Eduardo NavarroJPJuan Carlos Herrera Pérez

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Navarro et al. (2024) studied this question.

synapsesocial.com/papers/68e58b97b6db643587526e36https://doi.org/10.1159/000541364
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effects of cannabidiol on behavioral and psychological symptoms of vascular dementia: A randomized, double-blind, placebo-controlled clinical trial2025
  2. 2Effects of cannabidiol on behavioral and psychological symptoms of vascular dementia: A randomized, double-blind, placebo-controlled clinical trial2025
  3. 3Nabilone as Part of the Holistic Treatment in Early Onset Alzheimer's Dementia: A Case Study2024
  4. 4Can cannabinoids alleviate behavioral symptoms in older adults with dementia? A systematic review2025
  5. 5Cannabinoids for Behavioral Symptoms in Dementia: An Overview2024 · 6 citations